Electronic cigarettes (e-cigarettes) are increasing in popularity with 19% of UK smokers reporting to have used them. The ability to regulate the evaporation temperature in newer electronic nicotine delivery systems (ENDS) facilitates the potential for use of these devices to 'vape' cannabis, novel psychoactive substances (NPS) and other recreational drugs. Vaping cannabis does have the potential to reduce tobacco use and combustible cannabis/tobacco-related disease, but with over onethird of UK adults reporting life-time use of recreational drugs and increasing e-cigarette uptake in adolescent groups the misuse of these devices poses a serious potential public health risk. Further work is therefore urgently required to inform the appropriate treatment and primary prevention strategies for this emerging issue.
Introduction
Electronic cigarettes or 'E-cigarettes' and electronic nicotine delivery systems (ENDS) have exponentially increased in popularity since their introduction in 2004. In the UK, there has been an increase from 700 000 users in 2012-2.6 million in 2015, with 19% of UK smokers reporting to have used them. 1 These devices comprise a metal casing with a mouthpiece, a cartridge (or reservoir tank), a battery, an atomizer and a microprocessor. The user activates the device via pressure sensor inhalation or by pushing a button. The battery-powered atomizer produces an aerosolized vapour for inhalation ('vaping') by heating the 'e-liquid' in the cartridge. The liquid predominantly (90%) consists of the humectants propylene glycol and/or glycerine. These form the toxic irritant acrolein when burnt but is only generated to very low levels in vapour. 2 Water, flavourings and nicotine contribute to the rest of the liquid. Initially, the appearance, size, handling and oral inhalation characteristics of e-cigarettes were similar to tobacco cigarettes, this being an important part in their growing popularity.
Studies in the United States showed that in 2015 they were the most commonly used 'nicotine-product' in adolescent groups with the greatest rate of uptake among high school (3.9%) and college (13.4%) students. 3 Newer generation modified e-cigarettes or 'mods' now vary widely from large portable e-vapourizers, such as the Volcano table vapourizer, to smaller pen-style ENDS that are similar to e-cigarettes but contain larger reservoirs.
Novel uses
There has been increasing interest, particularly in the popular press, in the potential use of these devices to administer recreational drugs (http://www.dailymail.co.uk/news/article-2454693/E-cigarettes-used-smoke-marijuana-public.html). The ability to regulate the evaporation temperature in newer ENDS facilitates the potential for use of these devices to vape cannabis. Vaping trans-D 9 -tetrahydrocannabinol (THC), the main psy- Non-psychoactive cannabinoids, such as cannabidiol (CBD) are legally marketed and available as e-liquids in the UK for various pathologies such as the treatment of chronic pain syndromes and chemotherapy-induced nausea and vomiting. 4, 5 In the 24 US states that have fully legalized cannabis use in some form, suppliers have developed Cannabis products that include CBD and/or THC for use via vaping. Two of these commercially available e-cigarette liquid formulations reported to contain 3.3 mg/ml of CBD were evaluated by a group at Virginia Commonwealth University who found CBD in concentrations of 6.5 and 7.6 mg/ml, 7 suggesting issues with quality control of these products.
Rising tide of cannabis vaping
In a 2015 survey of 3847 students in five high schools in Connecticut, USA, 27.9% had used an e-cigarette; 29.2% had smoked cannabis and 5.4% had vaped cannabis by e-cigarette. 8 Rates of vapourizing cannabis were found to be higher amongst lifetime e-cigarette users (18.0%), lifetime cannabis users (18.4%) and lifetime dual cannabis and e-cigarette users (26.5%). Of those with previous e-cigarette use the odds ratio of vaping cannabis was 5.27 (95% CI 3.27-8.49), with the type of cannabis being vaped divided equally between hash oil and wax infused with THC used in e-cigarettes and dried cannabis leaves used in portable vapourizers. 9 Further studies corroborate the rising prevalence of vaping cannabis. Of 4269 US adults aged 18 years or over there was a 34.5% life-time prevalence of cannabis use with 9.9% reporting life-time vaping of cannabis and 7.6% reporting vaping of cannabis in the past month. 8 An online survey of a self-selected sample of 2923 cannabis users recruited via Facebook in 2016 reported that 61% had ever vaped cannabis. 10 The mean first vap- Harm reduction?
One of the greatest harms associated with smoking cannabis is its strong relationship with tobacco smoking. In adolescents, cannabis use has been found to be predictive of later tobacco smoking, and cannabis users may only be exposed to tobacco through smoking cannabis leading to nicotine dependence. 12 Vaping cannabis however can fully remove 'mulling' (mixing cannabis with tobacco) which may, in turn, reduce subsequent tobacco use. A 2014 study of 96 vapourizer users found that only 2% reported vaping cannabis combined with tobacco, whilst 16% would add tobacco when they smoked cannabis. 13 94% of participants in this study intended to continue using a vapourizer. Cannabis smoke is also comparable to tobacco smoke containing phenols, ammonia, hydrogen cyanide, nitrosamines and carcinogens such as benzopyrene and benzanthracene.
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2015 Public Health England review however estimates that ecigarette use is around 95% safer than cigarette smoke from this perspective as the harmful constituents of e-cigarette vapour are below 5% of smoking doses and far below safety limits for occupational exposure (https://www.gov.uk/government/up loads/system/uploads/attachment_data/file/457102/Ecigarettes _an_evidence_update_A_report_commissioned_by_Public_Heal th_England_FINAL.pdf). Consequently, vaping cannabis has the potential to reduce both tobacco use and combustible cannabis/ tobacco-related pulmonary and systemic disease. A 2010 study looking at lung function tests in 22 regular cannabis users with chronic cough and sputum bronchitic symptoms who smoked without mulling tobacco found a 10.6% increase in FEV1 and a 4.6% increase in FVC after switching to cannabis use by vapourizer for 30 days. 15 The overall pulmonary health benefit of vaping cannabis is probably limited though to a reduction in chronic bronchitis alone. Most lung function studies in regular cannabis smokers fail to find an association of significant airflow obstruction (COPD) after adjustment for concomitant tobacco use. 16 Fewer health benefits may be expected then for vaping cannabis than those projected for using e-cigarettes to replace smoking tobacco.
Synthetic cannabinoid receptor agonists and other recreational drugs
In addition to cannabis, online drug user forums have suggested substituting THC for soluble synthetic cannabinoid receptor agonists (SCRAs, colloquially known as 'Spice') such as APINACA (N-(1-adamantyl)-1-pentyl-1 H-indazole-3-carboxamide) and AB-FUBINACA (N-
(http://www.chemsrus.com/forum/10-cannabinoids/43770-creat ing-your-own-cannabinoid-eliquid). In contrast to the partial agonist effects of THC, many SCRAs are full agonists at cannabinoid receptors CB1R and CB2R giving greater potency and thus potentially more severe adverse effects. SCRAs can easily be mixed into e-liquids and vaped, they may also be sprayed onto inert aromatic herbs and vaped directly with modified e-cigarettes equipped with dry herb coil heads rather than those fitted with e-liquid cartridges. 4 Accurate prevalence data of SCRA use via vaping is lacking but on our review of drug user forums such as Erowid.org and Drugs-Forum.com 15% of people vaping cannabis have used SCRAs via this route. In addition, e-cigarettes can theoretically be used to vape any psychoactive drug that is heat stable.
Most of the information on the use of these devices for recreational drug and novel psychoactive substances (NPSs) comes from social media and internet drug forums. The first user report on Erowid.org was in 2007 for the use of the psychoactive plant Salvia divinorum. By December 2016, we had been able to identify 302 user reports on Erowid.org and Drugs-Forum.com related to the manufacture of e-liquids containing recreational drugs/NPS and/or their use. These sites also discuss anecdotal user reports of positive effects from vaping crystal methamphetamine, crack cocaine and LSD amongst others, whilst articles in online news sites discuss drug users adapting e-cigarettes to vape recreational drugs such as dimethyltryptamine (http://www.rt.com/uk/220551-vape-dmt-electronic-cigarette). Similarly, examples of using e-cigarettes to administer controlled substances such as Fentanyl extracted from patches (https://drugs-forum.com/forum/showthread.php?t¼4) are abundantly discussed on these forums.
Public health risk
Although the beneficial health effects associated with cannabis use are widely debated, regular use does pose absolute longterm health consequences from the harmful effects of THC on the central nervous system such as dependence, neurocognitive impairment; increased risk of psychosis in vulnerable populations and the potential for cardiovascular/cerebrovascular complications. 17 The proliferation of vaping SCRAs also heralds potentially more severe clinical adverse events over cannabis e.g. acute kidney injury, hypertensive emergencies and seizures as documented in a 2016 systematic review.
18
The limited published scientific data on vaping drugs other than cannabis means the prevalence is poorly understood. A literature search of Medline and EMBASE databases using the combined and exploded terms 'electronic cigarette', 'vaping', 'NPSs' and 'psychotropic drugs' found fifteen case reports of vaping NPS including: the synthetic opioid Acetylfentanyl causing respiratory depression responsive to naloxone 19 and the SCRA 'K2' with associated severe agitation and rhabdomyolysis resolving over 3 days with conservative management. 20 In 2015/16 over one-third (35.0%) of UK adults aged 16-59 reported life-time use of recreational/illicit drugs (https://www.gov. uk/government/statistics/drug-misuse-findings-from-the-2015-to-2016-csew). In combination with the emergence of vaping NPS and controlled substances, misuse of these drugs poses a serious potential public health risk due to: (i) lack of robust data on risks associated with vaping recreational drugs; (ii) increasing availability, use and acceptance of vaping devices, especially amongst teens and young adults, which may lead to greater use of illicit drugs by this route thereby increasing overall drug exposure; and (iii) the ability to vape deodorized drugs, especially cannabis, more discreetly with no smell (known as 'stealth vaping') making drug use harder to detect and therefore prevent.
Further work is therefore urgently required to inform the appropriate treatment and primary prevention strategies for this emerging issue.
Conclusion
The limited scientific data currently available suggests that vaping of cannabis and other recreational drugs is becoming increasingly popular, especially amongst adolescent groups, and it should therefore become part of the health providers' standard drug use history. From a public health perspective, concerns of lack of data on risks related to vaping recreational drugs warrant attention. A culture of vaping is emerging that includes the perceived positive attributes of vaping cannabis and the marketing of vaping devices not just for nicotine use. This novel culture could increase the prevalence of use; decrease the age of onset of use and lead to more problematic use of cannabis and other recreational drugs via vaping devices.
However, there could be reason to be optimistic about the potential of vaping as a route of cannabis use. Its increased uptake could lead to the dissociation of tobacco co-administration and subsequent reduction in tobacco use and dependence among cannabis users, resulting in reduced smoking associated harm. Although the comparatively greater harm reduction comes from vaping nicotine over smoking tobacco; if vaping cannabis became the common route, future cannabis users may never be exposed to tobacco in the first place. Studies are therefore required to look at vaping as an intervention in cannabis users to investigate whether cannabis vaping reduces subsequent use of tobacco. There is also an acute need to better understand the epidemiology and characterize the prevalence and current patterns of vaping recreational drugs, particularly NPS, an area in which there is little published data.
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